51719-65-4

Basic information

• Product Name: 2-(3,5-dichlorophenyl)acetic acid
• Synonyms: 2-(3,5-dichlorophenyl)acetic acid;3,5-Dichlorobenzeneacetic acid;3,5-Dichlorophenylacetic acid
• CAS NO: 51719-65-4
• Molecular Formula: C₈H₆Cl₂O₂
• Molecular Weight: 205.04
• Mol File: 51719-65-4.mol
• Article Data: 14

Chemical Properties

• Melting Point: 112-115 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 325.2 °C at 760 mmHg
• Flash Point: 150.5 °C
• Appearance: /Solid
• Density: 1.456 g/cm³
• Vapor Pressure: 9.54E-05mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 3.94±0.10(Predicted)
• CAS DataBase Reference: 2-(3,5-dichlorophenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-dichlorophenyl)acetic acid(51719-65-4)
• EPA Substance Registry System: 2-(3,5-dichlorophenyl)acetic acid(51719-65-4)

Safety Data

• Hazardous Substances Data: 51719-65-4(Hazardous Substances Data)

Usage

Description

2-(3,5-dichlorophenyl)acetic acid is an organic compound characterized by its chlorine atoms at the 3 and 5 positions on the phenyl ring, attached to an acetic acid group. It is a white crystalline solid with a chemical structure that provides it with unique properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
2-(3,5-dichlorophenyl)acetic acid is used as a reactant for the preparation of adenain inhibitors, which are potential antivirals. These adenain inhibitors can be developed into drugs that target and inhibit the adenain enzyme, a crucial component in the replication of certain viruses. By disrupting the viral replication process, these potential antivirals can help in the treatment and prevention of viral infections.

InChI:InChI=1/C8H6Cl2O2/c9-6-1-5(3-8(11)12)2-7(10)4-6/h1-2,4H,3H2,(H,11,12)

Upstream product

• 52516-37-7 3,5-dichlorophenylacetonitrile 
• 60211-57-6 3,5-dichlorobenzyl alcohol 
• 3290-06-0 1,3-dichloro-5-chloromethyl-benzene 
• 25186-47-4 3,5-dichlorotoluene 
• 7778-01-0 3,5-dichlorobenzyl bromide 
• 7732-18-5 water 
• 201230-82-2 carbon monoxide 
• 3032-81-3 3,5-dichloroiodobenzene 
• 64-19-7 acetic acid 

Downstream Products

• 56988-32-0 C₁₅H₈Cl₃NO₄ 
• 299956-57-3 (3,5-dichlorophenyl)acetyl chloride 
• 878541-84-5 1-{2-(4-bromobenzyl)-1-[(3,5-dichlorophenyl)acetyl]pyrrolidin-2-yl}propan-1-one 
• 878541-88-9 methyl 2-(4-cyanobenzyl)-1-[(3,5-dichlorophenyl)acetyl]pyrrolidine-2-carboxylate 
• 878541-85-6 {2-(4-bromobenzyl)-1-[(3,5-dichlorophenyl)acetyl]pyrrolidin-2-yl}(cyclopropyl)methanone 
• 936227-73-5 1-[2-(4-bromo-benzyl)-2-(1H-pyrazole-3-carbonyl)-pyrrolidin-1-yl]-2-(3,5-dichloro-phenyl)-ethanone 
• 220395-81-3 [2-(3,5-dichloro-phenyl)-pent-4-enyl]-methyl-amine 
• 209349-08-6 C₂₉H₃₂Cl₂N₂O₂S₂ 

Relevant articles and documents

An improved method for the synthesis of phenylacetic acid derivatives via carbonylation

2,4-Dichlorophenylacetic acid is synthesized in high yield via the carbonylation of 2,4-dichlorobenzyl chloride, and various experimental conditions are evaluated. Xylene, bistriphenylphosphine palladium dichloride, tetraethylammonium chloride and sodium hydroxide in solution are added to the reaction system and held at 80 °C under a CO atmosphere. 2,4-Dichlorophenylacetic acid is obtained in a maximum yield of 95percent, and a mechanism for 2,4-dichlorobenzyl chloride carbonylation is proposed. The reaction system provides a mild, effective and novel means by which to prepare phenylacetic acid derivatives from their corresponding benzyl chloride derivatives.

CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.